vabomere
Generic: meropenem and vaborbactam
vabomere: developed by 1 company · 1 clinical trial tracked.
vabomere evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect vabomere to MLNT; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could vabomere → MLNT affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Bacterial Infections
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Bacterial Infections | Phase 2 |
Clinical Trials (1)
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
Primary endpoint: Pharmacokinetics: AUC0-∞
Interventionalopen39 targetStarted 2016-07Completion 2026-129 sites · United StatesRempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Frequently asked questions
Who is developing vabomere?
vabomere is being developed by MELINTA THERAPEUTICS, INC. /NEW/.
How many clinical trials involve vabomere?
BioSniper tracks 1 clinical trial involving vabomere.